Matching Items (2)
Filtering by
- All Subjects: Protic Ionic Liquids
- Creators: Gould, Ian R
Description
The field of Ionic Liquid (IL) research has received considerable attention during the past decade. Unique physicochemical properties of these low melting salts have made them very promising for applications in a many areas of science and technology such as electrolyte research, green chemistry and electrodeposition. One of the most important parameters dictating their physicochemical behavior is the basicity of their anion. Using four sets of Protic Ionic Liquids (PILs) and spectroscopic characterization of them, a qualitative order for anion basicity of ILs is obtained.
Protic Ionic Liquids are made by proton transfer form a Brønsted acid to a base. The extent of this transfer is determined by the free energy change of the proton transfer process. For the cases with large enough free energy change during the process, the result is a fully ionic material whereas if the proton transfer is not complete, a mixture of ions, neutral molecules and aggregates is resulted. NMR and IR spectroscopies along with electrochemical and mechanical characterization of four sets of PILs are used to study the degree of ionicity.
Protic Ionic Liquids are made by proton transfer form a Brønsted acid to a base. The extent of this transfer is determined by the free energy change of the proton transfer process. For the cases with large enough free energy change during the process, the result is a fully ionic material whereas if the proton transfer is not complete, a mixture of ions, neutral molecules and aggregates is resulted. NMR and IR spectroscopies along with electrochemical and mechanical characterization of four sets of PILs are used to study the degree of ionicity.
ContributorsHasani, Mohammad (Author) / Angell, C. Austen (Thesis advisor) / Yarger, Jeffrey L (Committee member) / Gould, Ian R (Committee member) / Arizona State University (Publisher)
Created2016
Description
Mitochondria are crucial intracellular organelles which play a pivotal role in providing energy to living organisms in the form of adenosine triphosphate (ATP). The mitochondrial electron transport chain (ETC) coupled with oxidative phosphorylation (OX-PHOS) transforms the chemical energy of amino acids, fatty acids and sugars to ATP. The mitochondrial electron transport system consumes nearly 90% of the oxygen used by the cell. Reactive oxygen species (ROS) in the form of superoxide anions (O2*-) are generated as byproduct of cellular metabolism due to leakage of electrons from complex I and complex III to oxygen. Under normal conditions, the effects of ROS are offset by a variety of antioxidants (enzymatic and non-enzymatic).
Mitochondrial dysfunction has been proposed in the etiology of various pathologies, including cardiovascular and neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, ischemia-reperfusion (IR) injury, diabetes and aging. To treat these disorders, it is imperative to target mitochondria, especially the electron transport chain. One of the methodologies currently used for the treatment of mitochondrial and neurodegenerative diseases where endogenous antioxidant defenses are inadequate for protecting against ROS involves the administration of exogenous antioxidants.
As part of our pursuit of effective neuroprotective drugs, a series of pyridinol and pyrimidinol analogues have been rationally designed and synthesized. All the analogues were evaluated for their ability to quench lipid peroxidation and reactive oxygen species (ROS), and preserve mitochondrial membrane potential (Δm) and support ATP synthesis. These studies are summarized in Chapter 2.
Drug discovery and lead identification can be reinforced by assessing the metabolic fate of orally administered drugs using simple microsomal incubation experiments. Accordingly, in vitro microsomal studies were designed and carried out using bovine liver microsomes to screen available pyridinol and pyrimidinol analogues for their metabolic lability. The data obtained was utilized for an initial assessment of potential bioavailability of the compounds screened and is summarized fully in Chapter 3.
Mitochondrial dysfunction has been proposed in the etiology of various pathologies, including cardiovascular and neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, ischemia-reperfusion (IR) injury, diabetes and aging. To treat these disorders, it is imperative to target mitochondria, especially the electron transport chain. One of the methodologies currently used for the treatment of mitochondrial and neurodegenerative diseases where endogenous antioxidant defenses are inadequate for protecting against ROS involves the administration of exogenous antioxidants.
As part of our pursuit of effective neuroprotective drugs, a series of pyridinol and pyrimidinol analogues have been rationally designed and synthesized. All the analogues were evaluated for their ability to quench lipid peroxidation and reactive oxygen species (ROS), and preserve mitochondrial membrane potential (Δm) and support ATP synthesis. These studies are summarized in Chapter 2.
Drug discovery and lead identification can be reinforced by assessing the metabolic fate of orally administered drugs using simple microsomal incubation experiments. Accordingly, in vitro microsomal studies were designed and carried out using bovine liver microsomes to screen available pyridinol and pyrimidinol analogues for their metabolic lability. The data obtained was utilized for an initial assessment of potential bioavailability of the compounds screened and is summarized fully in Chapter 3.
ContributorsAlam, Mohammad Parvez (Author) / Hecht, Sidney M. (Thesis advisor) / Gould, Ian R (Committee member) / Moore, Ana (Committee member) / Arizona State University (Publisher)
Created2014